Epiomic Epidemiology Series: Multiple Sclerosis Forecast in 18 Major Markets 2017-2027

December 2016 | 98 pages | ID: E111FCEB652EN
Black Swan Analysis limited

Abstracts

Leukaemia refers to a group of cancers which originate in the bone marrow; they result in the overproduction of abnormal white blood cells. This limits the bone marrows ability to produce normal and fully mature white blood cells. Leukaemia classification is based on the speed of disease progression and the type of cells involved. The main subtypes are myeloid and monocytic, lymphoid or other; these can then be further subdivided into groups such as 'Acute' or 'Chronic'. Acute and chronic refer to the speed of disease progression. Whereas, myeloid, monocytic and lymphoid refer to the cell type affected.

This report provides the current incidence population for Leukaemia across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China, Turkey, Mexico, Russia, Argentina, Australia, Saudi Arabia and South Africa) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Leukaemia have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Leukaemia include:

• Haemolytic Anaemia
• Diabetes
• Frequent infections
• Headaches
• Cachexia

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global Leukaemia market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the incidence of the subdivided types of Leukaemia and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Leukaemia incident population.
• Identify sub-populations within Leukaemia which require treatment.
• Gain an understanding of the specific markets that have the largest number of Leukaemia patients.

Contents

Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key comorbid conditions associated with the disease
Methodology for quantification of patient numbers
Top-line prevalence for Multiple Sclerosis
  Diagnosis certainty
Features of Multiple Sclerosis patients
  Multiple Sclerosis Subtype
  Disability severity
  Abdominal pain
  Sleep problems
  Spasticity
  Urinary and bladder problems
Comorbidities in Multiple Sclerosis patients
  Features of MS patients with relapsing- remitting MS
  Features of MS patients with Secondary Progressive MS
  Features of MS patients with Primary Progressive MS
  Features of MS patients with Primary Relapsing MS
Abbreviations used in the report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

List Of Figures

LIST OF FIGURES

Demyelination in MS

List Of Tables

LIST OF TABLES

The McDonald criteria
Features and characteristics of the subtypes of MS
Prevalence of Multiple Sclerosis, total (000s)
Prevalence of Multiple Sclerosis, males (000s)
Prevalence of Multiple Sclerosis, females (000s)
Diagnosis Certainty of MS, total (000s)
MS subtype, total (000s)
Disability severity of MS patients, total (000s)
Severity of abdominal pain in MS patients, total (000s)
Severity of sleep problems in MS patients, total (000s)
Degree of Spasticity In MS patients, total (000s)
Nocturia in patients with MS, total (000s)
Activity leakage in MS patients, total (000s)
Urgency leakage in MS patients, total (000s)
MS patients with osteopenia, total (000s)
MS patients with diabetes, total (000s)
MS patients with hyperlipidaemia, total (000s)
MS patients with hypertension, total (000s)
MS patients with persistent bothersome pain, total (000s)
MS patients with RLS, total (000s)
MS patients with bone fractures after 3 yrs, total (000s)
MS current smokers, total (000s)
MS patients with neuropathic pain, total (000s)
MS patients with severe fatigue, total (000s)
RRMS with trigeminal neuralgia, total (000s)
RRMS with Lhermitte’s sign, total (000s)
RRMS with dysaesthesia, total (000s)
RRMS with painful muscle spasms, total (000s)
RRMS with back pain, total (000s)
RRMS with migraine, total (000s)
SRMS with trigeminal neuralgia, total (000s)
SPMS with Lhermitte’s sign, total (000s)
SPMS with dysaesthesia, total (000s)
SPMS with painful muscle spasms, total (000s)
SPMS with back pain, total (000s)
SPMS with migraine, total (000s)
PPMS with trigeminal neuralgia, total (000s)
PPMS with Lhermitte’s sign, total (000s)
PPMS with dysaesthesia, total (000s)
PPMS with painful muscle spasms, total (000s)
PPMS with back pain, total (000s)
PPMS with migraine, total (000s)
PRMS with trigeminal neuralgia, total (000s)
PRMS with Lhermitte’s sign, total (000s)
PRMS with dysaesthesia, total (000s)
PRMS with painful muscle spasms, total (000s)
PRMS with back pain, total (000s)
PRMS with migraine, total (000s)
Abbreviations and Acronyms used in the report
USA Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
USA Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Canada Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Canada Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
France Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
France Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Germany Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Germany Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Italy Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Italy Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Spain Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Spain Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
UK Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
UK Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Turkey Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Turkey Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Australia Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Australia Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Poland Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Poland Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Romania Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Romania Prevalence of Acne Vulgaris by 5-yr age cohort, females (000s)
Russia Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Russia Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Brazil Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Brazil Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Mexico Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Mexico Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Argentina Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Argentina Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Japan Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Japan Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
India Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
India Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
China Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
China Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)